Slidesets DSMM XIII: Phase III Trial of Rd Induction + ASCT With MEL140 Followed by R Maintenance vs Continuous Rd in Patients 60-75 Yr of Age With Newly Diagnosed MM Slidesets Phase II GEM-CESAR: Post Hoc Analyses of Sustained uMRD at 4 Yr After KRd + ASCT for High-Risk MM Slidesets MonumenTAL-1: Phase I/II Study of GPCR5D x CD3 Bispecific Antibody Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma Slidesets Phase II KarMMa-2 Cohort 2a: Idecabtagene Vicleucel in Patients With Multiple Myeloma With Early Relapse After Frontline ASCT Slidesets Phase I/II Trial of Mezigdomide + Dexamethasone in R/R MM: Preliminary Results From the Dose-Expansion Phase II Cohort Slidesets IFM 2017-03: Phase III Trial of Daratumumab + Lenalidomide vs Lenalidomide + Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma Slidesets Myeloma XI: Exploring Optimal Duration of Lenalidomide Maintenance After ASCT From Phase III Trial Slidesets ASCENT: Phase II Study of Fixed-Duration Therapy With Daratumumab/Carfilzomib/Lenalidomide/Dexamethasone for High-Risk Smoldering MM Slidesets UK OPTIMUM/MUKnine: Phase II Trial of Intensified Dara-VRd Consolidation After ASCT in Ultra-High‒Risk Newly Diagnosed Multiple Myeloma and Primary Plasma Cell Leukemia Slidesets Real-world Multicenter Retrospective Study of Idecabtagene Vicleucel in Patients With R/R MM After Previous BCMA-Targeted Therapy Exposure